HomeCompareCZAR vs GBDC

CZAR vs GBDC: Dividend Comparison 2026

CZAR yields 1.56% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.75M in total portfolio value
10 years
CZAR
CZAR
● Live price
1.56%
Share price
$30.06
Annual div
$0.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.9K
Annual income
$172.87
Full CZAR calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — CZAR vs GBDC

📍 GBDC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCZARGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CZAR + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CZAR pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CZAR
Annual income on $10K today (after 15% tax)
$132.80/yr
After 10yr DRIP, annual income (after tax)
$146.94/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,930,726.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CZAR + GBDC for your $10,000?

CZAR: 50%GBDC: 50%
100% GBDC50/50100% CZAR
Portfolio after 10yr
$10.40M
Annual income
$8,194,718.14/yr
Blended yield
78.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

CZAR
No analyst data
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CZAR buys
0
GBDC buys
2
PoliticianChamberTickerTypeAmountDate
David P. Joyce🏢 House$GBDC▼ Sell$1,001 - $15,0002023-06-30
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002023-06-19
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-14
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-12
Teresa Leger Fernandez🏢 House$GBDC▼ Sell$15,001 - $50,0002021-01-20
David P. Joyce🏢 House$GBDC▲ Buy$1,001 - $15,0002020-02-25
David P. Joyce🏢 House$GBDC▲ Buy$15,001 - $50,0002019-05-30
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCZARGBDC
Forward yield1.56%11.85%
Annual dividend / share$0.47$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$21.9K$20.78M
Annual income after 10y$172.87$16,389,263.41
Total dividends collected$1.7K$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: CZAR vs GBDC ($10,000, DRIP)

YearCZAR PortfolioCZAR Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$10,856$156.23$12,490$1,790.28$1.6KGBDC
2$11,775$158.52$16,522$3,157.73$4.7KGBDC
3$12,760$160.68$23,578$5,898.68$10.8KGBDC
4$13,815$162.73$37,115$11,886.75$23.3KGBDC
5$14,947$164.67$66,136$26,423.57$51.2KGBDC
6$16,160$166.50$137,257$66,491.44$121.1KGBDC
7$17,459$168.23$341,734$194,868.54$324.3KGBDC
8$18,852$169.87$1,050,788$685,133.02$1.03MGBDC
9$20,343$171.42$4,099,314$2,974,971.01$4.08MGBDC
10$21,939$172.87$20,775,530$16,389,263.41$20.75MGBDC

CZAR vs GBDC: Complete Analysis 2026

CZARStock

CZAR aims to mirror the performance of the Solactive Natural Monopoly Index, which includes global companies perceived to have a strong competitive edge within their sectors. The fund is focused on large- and mid-cap companies that meet certain requirements. This includes being part of a broader Solactive index aimed at Developed Markets, maintaining an average daily value traded, and meeting volume and free-float market capitalization percentage criteria. Stock selection for the fund is then based on fundamental financial metrics such as sales, profit margin, return on equity, inventory/total assets, and intangible assets/total assets. The top five firms within each sector are then chosen for the index. Weighting is designed to be sector-neutral, taking into consideration the free-float market capitalization of the index. Securities are then weighted equally within sectors, ensuring balanced exposure. CZAR is rebalanced seven business days after the semi-annual Selection Days in June and December.

Full CZAR Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this CZAR vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CZAR vs SCHDCZAR vs JEPICZAR vs OCZAR vs KOCZAR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.